20 May 2013
Keywords: positive, ph, ii, data, novartis, fty720, swiss
Article | 27 June 2005
Swiss drug major Novartis' candidate treatment for multiple sclerosis, FTY720, a novel, once-daily, oral medication, reduced the rate of
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 June 2005
17 May 2013
© 2013 thepharmaletter.com